Celldex Therapeutics (CLDX) Thoughts on EAACI and Phase 1b Barzolvolimab CSU Data - Cantor Fitzgerald
Tweet Send to a Friend
Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $59.00 price target on Celldex Therapeutics (NASDAQ: CLDX) after viewing ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
